Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DR-6MP Open Label Extension in Crohn's Disease
NCT01433432Phase 2Withdrawn
- Sponsor
- Teva Pharmaceutical Industries Ltd.
- Start
- Oct 2011
- Primary completion
- Jun 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of mercaptopurine in Crohn's disease (2 arms), sponsored by Teva Pharmaceutical Industries Ltd. Primary endpoint: Crohn's Disease Activity Index at 12 weeks. Planned start Oct 2011; status: withdrawn.
02
Drugs
mercaptopurine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01433432.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01433432.